Ronald Plott Biography and Net Worth

Director of Phio Pharmaceuticals

R. Todd Plott, MD, is a board-certified dermatologist, accomplished researcher, inventor, and former FDA advisory committee member with more than 30 years of experience in dermatologic care and innovation. He has played a significant role in advancing treatments for acne and other skin conditions through pharmaceutical research and development. Throughout his career, Dr. Plott oversaw and monitored hundreds of clinical trials, building deep expertise in drug development, clinical research, and patient care. He is now in private practice, focusing on complex skin diseases, acne, and skin cancer. Dr. Plott also served on the FDA Dermatologic and Ophthalmic Drug Advisory Committee from 2016 to 2021, reflecting his leadership and influence in the field of dermatology.

What is Ronald Todd Plott's net worth?: The estimated net worth of Ronald Todd Plott is at least $36.79 thousand as of September 28th, 2026. Dr. Plott owns 37,000 shares of Phio Pharmaceuticals stock worth more than $36,793 as of October 7th. This net worth evaluation does not reflect any other investments that Dr. Plott may own. Learn More about Ronald Todd Plott's net worth.
How do I contact Ronald Todd Plott?: The corporate mailing address for Dr. Plott and other Phio Pharmaceuticals executives is 411 Swedeland Road, Suite 23-1080, King OF Prussia, PA, 19406. Phio Pharmaceuticals can also be reached via phone at (508) 767-3861 and via email at [email protected]. Learn More on Ronald Todd Plott's contact information.
Has Ronald Todd Plott been buying or selling shares of Phio Pharmaceuticals?: Ronald Todd Plott has not been actively trading shares of Phio Pharmaceuticals during the past quarter. Most recently, on Monday, September 28th, Ronald Todd Plott bought 5,000 shares of Phio Pharmaceuticals stock. The stock was acquired at an average cost of $1.03 per share, with a total value of $5,150.00. Following the completion of the transaction, the director now directly owns 37,000 shares of the company's stock, valued at $38,110. Learn More on Ronald Todd Plott's trading history.
Who are Phio Pharmaceuticals' active insiders?: Phio Pharmaceuticals' insider roster includes Robert Bitterman (President & Chief Executive Officer), Patricia Bradford (Director), Gerrit Dispersyn (CEO), and Ronald Plott (Director). Learn More on Phio Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Phio Pharmaceuticals?: During the last year, Phio Pharmaceuticals insiders bought shares 8 times. They purchased a total of 53,500 shares worth more than $57,925.00. The most recent insider tranaction occured on September, 28th when Director Ronald Todd Plott bought 5,000 shares worth more than $5,150.00. Insiders at Phio Pharmaceuticals own 3.5% of the company. Learn More about insider trades at Phio Pharmaceuticals.
Information on this page was last updated on 9/28/2026.

Ronald Todd Plott Insider Trading History at Phio Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/28/2026	Buy	5,000	$1.03	$5,150.00	37,000
8/19/2026	Buy	15,000	$1.14	$17,100.00	15,000

Ronald Todd Plott Buying and Selling Activity at Phio Pharmaceuticals

Phio Pharmaceuticals Company Overview

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

Today's Range

Now: $1.01

$0.99

$1.02

50 Day Range

MA: $1.06

$0.98

$1.21

2 Week Range

Now: $1.01

$0.81

$4.19

Volume

17,770 shs

Average Volume

1,471,138 shs

Market Capitalization

$11.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84